Neumora Therapeutics, Inc. 8K

Neumora Therapeutics is discontinuing navacaprant after failed Phase 3 MDD trials, cutting about 35% of its workforce, and reallocating resources to its remaining CNS and cardiometabolic pipeline programs, with cash runway projected into Q3 2027.

On June 15, 2026, Neumora Therapeutics, Inc. reported that its Phase 3 KOASTAL‑2 and KOASTAL‑3 trials of navacaprant in major depressive disorder failed to achieve statistical significance on the primary or key secondary endpoints, leading the company to discontinue further development of navacaprant and restructure its operations, including a workforce reduction of approximately 35% expected to yield about $10 million in annualized cost savings offset by roughly $2 million in one‑time restructuring charges. The company is refocusing its pipeline on three remaining programs—NMRA‑511 for Alzheimer’s disease agitation, NMRA‑898 for schizophrenia, and NMRA‑215 for obesity/cardiometabolic disease—with specific clinical and toxicology milestones planned through year‑end 2026, and it stated that existing cash and cash equivalents are expected to fund operations into the third quarter of 2027 while supporting multiple upcoming clinical catalysts.

Filing Facts

CIK

1885522

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-270328

Alert Tier

7